Big Pharma's Drug Failure May Be Small Personalized Rx Firm's Gain, PGx Researcher Says | GenomeWeb

By Turna Ray

Using pharmacogenomics to resuscitate a drug that has previously failed clinical trials due to safety issues is one strategy no large pharmaceutical firm has yet had the guts to attempt in the US. However, this approach could reap benefits for smaller firms willing to license big pharma’s failed drugs, a speaker at a recent conference suggested.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.